The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Sodium Zirconium Cyclosilicate in Hyperkalemia
Open accessAbstract
BACKGROUND: Hyperkalemia (serum potassium level, >5.0 mmol per liter) is associated with increased mortality among patients with heart failure, chronic kidney disease, or diabetes. We investigated whether sodium zirconium cyclosilicate (ZS-9), a novel selective cation exchanger, could lower serum potassium levels in patients with hyperkalemia. METHODS: In this multicenter, two-stage, double-blind, phase 3 trial, we randomly assigned 753 patients with hyperkalemia to receive either ZS-9 (at a dose of 1.25 g, 2.5 g, 5 g, or 10 g) or placebo three times daily for 48 hours. Patients with normokalemia (serum potassium level, 3.5 to 4.9 mmol per liter) at 48 hours were randomly assigned to receive either ZS-9 or placebo once daily on days 3 to 14 (maintenance phase). The primary end point was the exponential rate of change in the mean serum potassium level at 48 hours. RESULTS: At 48 hours, the mean serum potassium level had decreased from 5.3 mmol per liter at baseline to 4.9 mmol per liter in the group of patients who received 2.5 g of ZS-9, 4.8 mmol per liter in the 5-g group, and 4.6 mmol per liter in the 10-g group, for mean reductions of 0.5, 0.5, and 0.7 mmol per liter, respectively (P<0.001 for all comparisons) and to 5.1 mmol per liter in the 1.25-g group and the placebo group (mean reduction, 0.3 mmol per liter). In patients who received 5 g of ZS-9 and those who received 10 g of ZS-9, serum potassium levels were maintained at 4.7 mmol per liter and 4.5 mmol per liter, respectively, during the maintenance phase, as compared with a level of more than 5.0 mmol per liter in the placebo group (P<0.01 for all comparisons). Rates of adverse events were similar in the ZS-9 group and the placebo group (12.9% and 10.8%, respectively, in the initial phase; 25.1% and 24.5%, respectively, in the maintenance phase). Diarrhea was the most common complication in the two study groups. CONCLUSIONS: Patients with hyperkalemia who received ZS-9, as compared with those who received placebo, had a significant reduction in potassium levels at 48 hours, with normokalemia maintained during 12 days of maintenance therapy. (Funded by ZS Pharma; ClinicalTrials.gov number, NCT01737697.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Goraya, N., Simoni, J., Jo, C.-H., & Wesson, D. E. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02430312 · Cited by 410
Goraya, N., Simoni, J., Jo, C.-H., & Wesson, D. E. (2014) · Kidney International · doi:10.1038/ki.2014.83 · Cited by 399
Aaron, K. J., & Sanders, P. W. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.06.005 · Cited by 359
Harel, Z., Harel, S., Shah, P. S., Wald, R., Perl, J., & Bell, C. M. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.08.016 · Cited by 322
Ion-Exchange Resins for the Treatment of Hyperkalemia: Are They Safe and Effective?
Sterns, R. H., Rojas, M., Bernstein, P., & Chennupati, S. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010079 · Cited by 303
Severe hyperkalemia requiring hospitalization: predictors of mortality
An, J. N., Lee, J. P., Jeon, H. J., Kim, D. H., Oh, Y. K., Kim, Y. S., & Lim, C. S. (2012) · Critical Care · doi:10.1186/cc11872 · Cited by 291
Predictors of Hyperkalemia and Death in Patients With Cardiac and Renal Disease
Jain, N., Kotla, S., Little, B. B., Weideman, R. A., Brilakis, E. S., Reilly, R. F., & Banerjee, S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.01.367 · Cited by 218
Vardeny, O., Claggett, B., Anand, I., Rossignol, P., Desai, A. S., Zannad, F., Pitt, B., & Solomon, S. D. (2014) · Circulation: Heart Failure · doi:10.1161/circheartfailure.114.001104 · Cited by 209
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0141 · Cited by 444
Collins, A. J., Pitt, B., Reaven, N., Funk, S., McGaughey, K., Wilson, D., & Bushinsky, D. A. (2017) · American Journal of Nephrology · doi:10.1159/000479802 · Cited by 403
Metadata
- Authors
- Packham, D. K., Rasmussen, H. S., Lavin, P. T., El-Shahawy, M. A., Roger, S. D., Block, G., Qunibi, W., Pergola, P., & Singh, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-15
- Volume
- 372
- Issue
- 3
- Pages
- 222-231
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2041162893
- Cited by
- 506
- References
- 27
- FWCI
- 35.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sodium Zirconium Cyclosilicate in Hyperkalemia. https://app.cochat.ai/papers/10.1056/nejmoa1411487
- The paper
- Packham, D. K., Rasmussen, H. S., Lavin, P. T., El-Shahawy, M. A., Roger, S. D., Block, G., Qunibi, W., Pergola, P., & Singh, B. (2015). Sodium Zirconium Cyclosilicate in Hyperkalemia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1411487
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.